Fri, Jan 30, 2015, 6:28 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Pacific Biosciences of California, Inc. Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    News out!

    by gettinricher Jan 5, 2015 8:00 AM

    Looks like all the companies using this equipment must think it's the bomb, and are probably many of those who have been accumulating this stock lately. It's been an under the radar climber that's for sure.

    Sentiment: Strong Buy

  • Reply to

    News out!

    by gettinricher Jan 5, 2015 8:00 AM

    Looks like more and more are using SMRT Sequencing tech. Unbelievable how much interest has grown in just the past year. Really looking forward to what the new equipment will be like. In my opinion, they could take over Illumina's spot in this field no problem.

    Sentiment: Strong Buy

  • Pacific Biosciences Customers Present Work on Complex De Novo Genomes and Genome Annotation at the International Plant & Animal Genome XXIII Conference
    GlobeNewswire22 minutes ago
    Companies mentioned
    PACB
    $7.81 USD$0.00(0.00%)

    Add to watchlist | Set alert | Trade
    You currently hold Pacific Biosciences of California Inc
    MENLO PARK, Calif., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc., (Nasdaq:PACB) provider of the PacBio® RS II Sequencing System, today announced its participation in the International Plant & Animal Genome (PAG) XXIII Conference taking place in San Diego from January 10-14. More than 50 researchers from around the world will be presenting their work, many representing large consortium efforts, using Single Molecule, Real-Time (SMRT®) Sequencing to assemble de novo and/or analyze complex genomes from a variety of plants and animals.
    The company will hold a workshop on January 13 from 1:30-3:30 p.m. where current PacBio customers from the Arabica Coffee Genome Consortium, Keygene and the USDA will present SMRT Sequencing results on their genome projects for coffee, cotton, and goat, respectively. The winner of last year's "The Most Interesting Genome in the World" grant program, Dr. Robert VanBuren from Donald Danforth Plant Science Center, will also present his data on the Oropeitum thomaeum (Oro) genome, a grass that can tolerate extreme desiccation and regrow once water is again available and which could provide important insights into mechanisms that can potentially improve drought resistance in crops.
    "The Most Interesting Genome in the World" grant program will again be held at this year's conference, providing the opportunity for researchers to submit their proposal to have their genome of interest sequenced on the PacBio RS II. Co-sponsors of the program include Sage Science, Computomics, and the Arizona Genomics Institute. More details are available at: www.pacb.com/smrtgrant.
    Companies in the news
    PACB
    Pacific Biosciences of California Inc
    $7.81
    0.00%
    As of 7:51a ET 1/5/2015. Quotes are delayed by at least 15 minutes.
    "Overall, we have seen tremendous progress from researchers working with larger, more complex genomes in the plant and animal space and are pleased to see more than 50 presentations using SMRT Sequencing on the agenda." said Kevin Corcoran, Senior Vice President, Market Development for Pacific Biosciences. "Since last year's PAG meeting, many more customers have taken advantage of our Iso-Seq™ application for full-length transcript sequencing and together we are looking forward to sharing more about the advantages of this approach for discovering novel genes and gene isoforms."
    About the PacBio RS II and SMRT Sequencing
    Pacific Biosciences' SMRT Sequencing technology achieves the industry's longest read lengths, highest consensus accuracy, and the least degree of bias. These characteristics, combined with the ability to detect many types of DNA base modifications (e.g., methylation) as part of the sequencing process, make the PacBio RS II an essential tool for many scientists studying genetic and genomic variation. The PacBio platform provides a sequencing solution that can address a growing number of complex medical, agricultural, and industrial problems.
    About Pacific Biosciences
    Pacific Biosciences of California, Inc. (Nasdaq:PACB) offers the PacBio RS II DNA Sequencing System to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT) technology, the company's products enable: targeted sequencing to more comprehensively characterize genetic variations; de novo genome assembly to more fully identify, annotate, and decipher genomic structures; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. By providing access to information that was previously inaccessible, Pacific Biosciences enables scientists to increase their understanding of biological systems. More information is available at www.pacb.com
    CONTACT: Media:
    Nicole Litchfield
    415.793.6468
    nicole@bioscribe.com

    Investors:
    Trevin Rard
    650.521.8450
    ir@pacificbiosciences.com

    Sentiment: Strong Buy

  • May see low 7/high6 again but the trend is definitively upwards since 2013. Got in at around 5 and tempted to run with my 50% gain but I really think PACB will hit double digits this year. If there is a temporary pull back I may buy more (hate to dollar cost average up but that means the stock is going up :0)). Happy new year.

    Sentiment: Strong Buy

  • Almost touched the 52 week high intraday just a few days back. Very bullish. Very nice accumulation going on lately, especially since it's usually end of year tax selling going on in most other stocks. Also very bullish. Wondering if we see another milestone payment yet this quarter, and wondering also how long we will have to wait to see the new euipment unvailed. I also hold this one long term. This stock has alot of room to run,that is if we don't get taken out. All you need to do is look at who's who on the board, and especially the last couple added. I still don't get why they almost seem to hide the fact that they are going to the big conferences, like the upcoming JP Morgan 33rd annual Healthcare conf., that they will be attending Jan. 12-15th. It isn't shown on their main webpage like the others, you have to jump around under events and presentations to find this out. Almost like they don't want it to be known. I'm sure they have a good reason, because they have a great mgt.team in place. Anyway I hope to be hearing news in the near future. GLTAL's, and Happy New Year.

    Sentiment: Strong Buy

  • I'm trying to predict the trend with this one. I'm holding long term. Hope to see it at least billion dollar market cap.

  • I see lot of speculation in bullishness. Lot of up side calls, but no high-end puts...Be careful if you are looking for quick bucks...I'm bullish on PACB because it's rewriting the gold standards in sequencing and driving very interesting research that couldn't have been done with ABI, 454, Illumina, and still waiting for nanopore...

  • Seems like a lot of $7.50 calls were EXECUTED! VERY VERY bullish!

    Sentiment: Strong Buy

  • Reply to

    Welcome aboard to Kathy Ordonez

    by gettinricher Dec 18, 2014 9:42 AM

    What I find most interesting is the specific background of Kathy. Her career history, as presented in the press release, is clearly focused on commercialization of diagnostic tools. I think this lends credibility to the thesis that PacBio has a diagnostic tool in the pipeline that has serious potential for commercial viability.

    My wishful thinking / dream insight is to note that her diagnostic tool company was acquired by Roche. Could this appointment be at all related to positioning PacBio for a Roche buyout???

    What's hard for me as a shareholder at this point is that we have serious price appreciation this year without, in my judgment, sufficient newswire justification. This company landed on my radar because of the single day gains when the deal with Roche was struck. I basically accumulated a position over the last year without knowing jack (the valuation is obviously very far ahead of fundamentals, including company guidance). I'm not very well versed in biotech, much less DNA sequencing technologies. So do I sell now and take my substantial gains (avg of 5.50ish)? Or do I hold? It seems clear that these guys have a superior technical advantage, but are commercially out maneuvered by ILMN for practical applications. The whole notion that PACB and ILMN are actually complementary technologies is nice, but it's not exactly translating into a metric I can quantify and predict. So my thesis basically revolves around this diagnostic tool making PACB's product commercially viable on a large scale.

    Sentiment: Hold

  • Any thoughts on whether we see Roche deliver us another milestone payment before the quarter ends? If so, how much this time? Another 10 million, maybe only 5 million this time,maybe 15 million? While we're at it, any guess as to when this new diagnostic equipment gets debuted?

    Sentiment: Strong Buy

  • Reply to

    Welcome aboard to Kathy Ordonez

    by gettinricher Dec 18, 2014 9:42 AM

    you don't sell a company with great product in its infancy.

  • Kathy Ordoñez brings more than 30 years of experience in the life sciences and diagnostics industries. As Senior Vice President at Quest Diagnostics, Ms. Ordonez was initially responsible for leading the company’s R&D effort and later provided oversight to multiple businesses commercializing diagnostic products and testing services. She joined Quest Diagnostics as part of its acquisition of Celera Corporation in 2011. Ms. Ordoñez was previously the Chief Executive Officer at Celera and a founder of Celera Diagnostics. Under her leadership, Celera became the leading producer of genetic testing products for HIV resistance, cystic fibrosis and high complexity tissue transplantation. Earlier in her career, Ms. Ordoñez held several senior positions at Hoffmann La-Roche, overseeing the formation of Roche Molecular Systems, where she served as President and Chief Executive Officer, and led the wide-scale commercial application of the Polymerase Chain Reaction (PCR) technology to the research, diagnostic and forensic fields.

  • Reply to

    Welcome aboard to Kathy Ordonez

    by gettinricher Dec 18, 2014 9:42 AM

    what sells is the product and who ever wants to buy their platforms or take over the company already knows about them. off course if they were selling toothpaste then connection would matter. bringing your buddies to the board of directors is just rubbing each others back. all I am saying is not getting excited about this news but I am excited about the future of the company with or without her.

  • Reply to

    Welcome aboard to Kathy Ordonez

    by gettinricher Dec 18, 2014 9:42 AM

    Big shot board members come with experience, that is beneficial to management.

    Do you think that Kathy Ordonez's vast experience is not beneficial to PACB?

    Ideas, and other connections in the business come with board members.

    I personally have had other stocks that new big shot board members were instrumental in the company being acquired by their previous employers.

  • Reply to

    Welcome aboard to Kathy Ordonez

    by gettinricher Dec 18, 2014 9:42 AM

    Big shot board members come with experience, that is beneficial to management.

    Do you think that Kathy Ordonez's vast experience is not beneficial to PACB?

    Ideas, and other connections in the business come with board members.

    I personally have had other stocks that new big shot board members were instrumental in the company being acquired by their previous employers.

  • Reply to

    Welcome aboard to Kathy Ordonez

    by gettinricher Dec 18, 2014 9:42 AM

    Drive better deal of course.

  • Reply to

    Welcome aboard to Kathy Ordonez

    by gettinricher Dec 18, 2014 9:42 AM

    then why do you need both of them. extra overhead.

  • Reply to

    Welcome aboard to Kathy Ordonez

    by gettinricher Dec 18, 2014 9:42 AM

    I am referring to big shot board members and not the management.

  • Reply to

    Welcome aboard to Kathy Ordonez

    by gettinricher Dec 18, 2014 9:42 AM

    boja4...The current stock activity is disagreeing with your opinion.

    If you think superior management has no bearing on the value of the underlying company, you are very mistaken.

    Your analysis of their function in the company is at best comical.

    Experience is the best teacher, experienced management may not make any difference to you, but I'm thinking you are definitely in the minority.

PACB
8.04-0.130(-1.59%)Jan 30 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.